CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will

Announcing Positive Phase 3 Results for Zuranolone, an Investigational Two-Week, Once Daily Therapeutic Being Evaluated for Major Depressive Disorder Webcast scheduled for 8:00a.m. ET on Tuesday, June 15 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2021-- Sage Therapeutics (Nasdaq: SAGE), a

At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in HAMD-17 results at Days 3, 8, and 12 Patients with a

Creating a movement from the inside out – to break the stigma of mental health conditions and empower employees to be champions of brain health Learn more at www.MentalHealthActionDay.org CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 20, 2021-- Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company

Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m.

Company on-track to initiate placebo-controlled Phase 2 trial with SAGE-718 in Huntington’s disease in late 2021, as the target for the first indication for SAGE-718, following encouraging signals in Phase 1 data PARADIGM Study with SAGE-718 showed improved performance from baseline on multiple

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

Statistically significant reduction in tremor score compared to placebo at Day 29 in adults with essential tremor SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb